Key result
Rosuvastatin pretreatment did not attenuate microalbuminuria after CABG surgery and resulted in a significantly higher albumin/creatinine ratio at 6 hours postoperatively compared to control (2.10 vs 0.69, p=0.002).
Why the study?
Does rosuvastatin pretreatment reduce microalbuminuria and the systemic inflammatory response in patients undergoing coronary artery bypass grafting?
RCT (n=40)
Placebo-controlled
Randomized
No
Does rosuvastatin pretreatment reduce microalbuminuria and the systemic inflammatory response in patients undergoing coronary artery bypass grafting?
Absolute Event Rate: 2.1% vs 0.69%
p-value: p=0.002
Preoperative rosuvastatin therapy does not attenuate microalbuminuria or the systemic inflammatory response in patients undergoing coronary artery bypass grafting.
Rosuvastatin pretreatment should not be used to reduce microalbuminuria after CABG; challenges presumed perioperative anti-inflammatory benefits of statins.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Serkan Seçici (2014) conducted an RCT in Coronary artery disease requiring CABG (n=40). Rosuvastatin vs. Placebo was evaluated on Urinary albumin/creatinine ratio at 6 hours postoperatively in the intensive care unit (p=0.002). Rosuvastatin pretreatment did not attenuate microalbuminuria after CABG surgery and resulted in a significantly higher albumin/creatinine ratio at 6 hours postoperatively compared to control (2.10 vs 0.69, p=0.002).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: